Complete and send the form, together with applicable fee(s), to: Mail OUT 0 4 2004 NSTRUCTURE ST. This is should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be complaypropriate. In the property of the part of the property of the part of	lings of the companying wing, must the Unite an envelop g facsimil low. Ositor's name (Signature (Date ON NO.
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) 23492 7590 08/19/2004 STEVEN F. WEINSTOCK ABBOTT LABORATORIES 100 ABBOTT PARK ROAD DEPT. 377/AP6A ABBOTT PARK, IL 60064-6008 PATENT DEPARTMENT 10/05/2004 FMETEKI2 00000110 010025 1 FC:1501 1370.00 DA 2 FC:1504 300.00 DA 300.00	lings of the companying wing, must the Unite an envelop g facsimil low. Ositor's name (Signature (Date ON NO.
23492 7590 08/19/2004 STEVEN F. WEINSTOCK ABBOTT LABORATORIES 100 ABBOTT PARK ROAD DEPT. 377/AP6A ABBOTT PARK, IL 60064-6008 0/05/2004 FMETEKI2 00000110 010025 10616628 1 FC:1504 300.00 DA APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATI 10/616,628 07/10/2003 Megumi Kawai 6357.US.D1 3368 TITLE OF INVENTION: ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DOND TOTAL FEE(S) DUE DATE DATE DATE DATE DATE DATE DATE DAT	the Unite an envelop g facsimil low. (Signature (Date
ABBOTT LABORATORIES 100 ABBOTT PARK ROAD DEPT. 377/AP6A ABBOTT PARK, IL 60064-6008 0/05/2004 FMETEKI2 00000110 010025 10616628 1 FC:1501 1370.00 DA 2 FC:1504 300.00 DA 2 FC:1504 300.00 DA 3 TITLE OF INVENTION: ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE D nonprovisional NO \$1330 \$300 \$1630 \$11/19/20	(Signature (Date
APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DOOR TO TOTAL FEE(S) DOOR TO TOTAL FEE	(Signature (Date
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION 10/616,628 07/10/2003 Megumi Kawai 6357.US.D1 3368 TITLE OF INVENTION: ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DO NO \$1330 \$300 \$1630 \$11/19/20	(Date
APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATE 10/616,628 07/10/2003 Megumi Kawai 6357.US.D1 3368 TITLE OF INVENTION: ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE DO NO \$1330 \$300 \$1630 \$11/19/20 EXAMINER ART UNIT CLASS-SUBCLASS	ON NO.
10/616,628 07/10/2003 Megumi Kawai 6357.US.D1 3368 TITLE OF INVENTION: ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE D nonprovisional NO \$1330 \$300 \$1630 11/19/20	-
TITLE OF INVENTION: ANTIANGIOGENIC DRUG TO TREAT CANCER, ARTHRITIS AND RETINOPATHY APPLN. TYPE SMALL ENTITY ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE DATE D nonprovisional NO \$1330 \$300 \$1630 11/19/20 EXAMINER ART UNIT CLASS-SUBCLASS	
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Change of correspondence address or indication of "Fee Address" indication form PTO/SB/122) attached. Change of correspondence address or indication of "Fee Address" (37 (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.	orbin
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has be recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.	en filed fo
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) Abbott Laboratories Abbott Park, IL	
Please check the appropriate assignee category or categories (will not be printed on the patent);	governmer
4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):	
Issue Fee	
Publication Fee (No small entity discount permitted) Advance Order - # of Copies	

☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

b. Applicant is not claiming SMALL ENTITY status. See, e.g., 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in

interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature) (Date)

10 This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.